Corporate Information


  • Established June 1, 2007
  • Main office 3-2-7 Korai-bashi, Chuo-ku, Osaka, Osaka Prefecture 541-0043
  • Description of business Research, development, manufacturing, and sales of pharmaceuticals and medical devices
  • Capital 1.9 billion yen
  • Shareholders Stella Chemifa, Innovation Network Corporation of Japan, Sumitomo Heavy Industries, Ltd.
  • President Tomoyuki Asano
  • Number of employees 40 (as of May 2018)
  • Laboratory Sakai R&D Center, Tokyo Office


  • June 2007 Stella Pharma founded
  • July 2008 First-class marketing license for pharmaceuticals obtained (Osaka Prefecture)
  • December 2013 First-class marketing license for medical devices obtained (Osaka Prefecture)
  • January 2014 The Sanpo and Nakamozu laboratories merged with the Sakai R&D Center

Corporate strategy

  • To faithfully uphold the Act on Pharmaceuticals and Medical and Devices and related laws and regulations including GMP, GCP and GQP while developing new products.
  • To establish an organization that is suited for the pharmaceutical and medical device industry and strives for continuous improvement.
  • To enhance our mission and moral values as a provider of pharmaceutical products and medical devices through education and practice.